DiaMedica Therapeutics Net Income

The latest net income for DMAC is $-35M as of March 2026. That compares with $-27M in the prior-year period — down 30.0% year over year. That is below the Healthcare sector average of $17B. Investors often review this figure alongside DiaMedica Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, DMAC's net income moved from $-27M to $-35M — a 30.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in DiaMedica Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, DMAC currently prints $-35M for net income, while the sector average sits near $17B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at DiaMedica Therapeutics's growth, margins, and balance sheet.

A net income figure of $-35M for DMAC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $17B. Explore the charts below for those layers of context.

After noting DMAC's net income ($-35M), review year-over-year change from $-27M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.